摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氯嘧啶-5-硼酸频哪酯 | 1003845-08-6

中文名称
2-氯嘧啶-5-硼酸频哪酯
中文别名
2-氯嘧啶-5-硼酸频那醇酯;2-氯-5-嘧啶硼酸频哪醇酯
英文名称
2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine
英文别名
2-chloropyrimidine-5-boronic acid pinacol ester
2-氯嘧啶-5-硼酸频哪酯化学式
CAS
1003845-08-6
化学式
C10H14BClN2O2
mdl
MFCD11856048
分子量
240.497
InChiKey
VLAPDEKXZLRRKV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    65.0 to 69.0 °C
  • 沸点:
    369.1±15.0 °C(Predicted)
  • 密度:
    1.19±0.1 g/cm3 (20 ºC 760 Torr)

计算性质

  • 辛醇/水分配系数(LogP):
    2.64
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    44.2
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335

SDS

SDS:610d29e88951edbf5f531f6969243aff
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Chloropyrimidine-5-boronic acid pinacol ester
Synonyms: 2-Chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloropyrimidine-5-boronic acid pinacol ester
CAS number: 1003845-08-6

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H14BClN2O2
Molecular weight: 240.5

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

2-氯嘧啶-5-硼酸频那醇酯主要用于制备吲哚衍生物,并作为选择性的Pim激酶抑制剂展现出广泛的药理活性。此外,它还被用于制备TGF-β1抑制剂和激活素A信号转导。因此,这类化合物是一类重要的化工产品及关键医药中间体。

制备

以5-溴-2-氯嘧啶为原料,在Pd催化体系下,使用B2(pin)2作为硼试剂,在室温条件下合成其硼酸酯,具体合成路线如下图所示:

嘧啶-5-硼酸频哪醇酯合成路线图

研究表明,以5-溴-2-氯嘧啶为原料,在0.5 mol% Xphos-Pd-G2和0.25 mol% Xphos催化体系下,使用B2(pin)2作为硼试剂、7水合磷酸钾为碱、乙醇为溶剂,在室温下反应1小时,可以高效制备嘧啶-5-硼酸频哪醇酯。该方法具有原料廉价易得、官能团兼容性好、条件温和、操作简便、反应高效且适合大量生产等优点。

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-氯嘧啶-5-硼酸频哪酯四(三苯基膦)钯 作用下, 以88.29%的产率得到2-((6-(2-chloropyrimidin-5-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile
    参考文献:
    名称:
    AUTOTAXIN INHIBITOR COMPOUNDS
    摘要:
    本公开提供了自动脂肪酸酯酶(ATX)抑制剂化合物和包括该化合物的组合物。本公开还提供了使用该化合物和组合物抑制ATX的方法。还提供了制备该化合物和组合物的方法,以及该化合物的合成前体。
    公开号:
    US20220106311A1
  • 作为产物:
    描述:
    频哪醇2-氯嘧啶-5-硼酸 在 magnesium sulfate 作用下, 以 甲苯 为溶剂, 反应 15.0h, 以100%的产率得到2-氯嘧啶-5-硼酸频哪酯
    参考文献:
    名称:
    ORGANIC COMPOUNDS
    摘要:
    本发明提供了一种化合物,其化学式为(I):其中变体R1、R2、R3、R4、R5、R6、R7如本文所定义,并且所述化合物是CETP的抑制剂,因此可用于治疗由CETP介导或对CETP抑制响应的疾病或疾病。
    公开号:
    US20090118287A1
点击查看最新优质反应信息

文献信息

  • [EN] POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES<br/>[FR] COMPOSÉS POLYCYCLIQUES ET MÉTHODES POUR LA DÉGRADATION CIBLÉE DE POLYPEPTIDES DU FIBROSARCOME RAPIDEMENT ACCÉLÉRÉ
    申请人:ARVINAS OPERATIONS INC
    公开号:WO2020051564A1
    公开(公告)日:2020-03-12
    The present disclosure relates to bifunctional compounds, ULM— L—PTM, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A- RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.
    本公开涉及双功能化合物ULM—L—PTM,其作为快速加速纤维肉瘤(RAF,如c-RAF、A-RAF和/或B-RAF;目标蛋白)的调节剂具有实用性。具体而言,本公开涉及含有一端结合到相应E3泛素连接酶的Von Hippel-Lindau、cereblon、凋亡抑制蛋白或鼠双分子同源物2配体的双功能化合物,另一端结合到目标蛋白RAF的部分,使得目标蛋白与泛素连接酶靠近,以实现目标蛋白的降解(和抑制)。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性范围。本公开的化合物和组合物用于治疗或预防由目标蛋白的聚集或积累,或目标蛋白的构成性激活导致的疾病或紊乱。
  • [EN] TRICYCLIC MODULATORS OF TNF SIGNALING<br/>[FR] MODULATEURS TRICYCLIQUES DE LA SIGNALISATION DU TNF
    申请人:ABBVIE INC
    公开号:WO2016168641A1
    公开(公告)日:2016-10-20
    The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, prodrugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    这项发明提供了三环杂环化合物,其药用盐、前药、生物活性代谢物、立体异构体和同分异构体,其中变量在此处定义。该发明的化合物可能对治疗免疫和肿瘤疾病有用。
  • [EN] FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY<br/>[FR] DÉRIVÉS D'IMIDAZOLE ET DE PYRAZOLE CONDENSÉS COMME MODULATEURS DE L'ACTIVITÉ DU TNF
    申请人:UCB BIOPHARMA SPRL
    公开号:WO2015086512A1
    公开(公告)日:2015-06-18
    A series of substituted benzimidazole, imidazo[1,2-α]pyridine and pyrazolo[1,5- α]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    一系列取代苯并咪唑、咪唑并[1,2-α]吡啶和吡唑并[1,5-α]吡啶衍生物及其类似物,作为人类TNFα活性的有效调节剂,因此在治疗和/或预防各种人类疾病方面具有益处,包括自身免疫和炎症性疾病;神经学和神经退行性疾病;疼痛和伤害感知性疾病;心血管疾病;代谢性疾病;眼科疾病;以及肿瘤学疾病。
  • [EN] HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILES EN TANT QUE MODULATEURS DU TNF ALPHA
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2017023905A1
    公开(公告)日:2017-02-09
    Disclosed are compounds of Formula (I) or a salt thereof, wherein: A is CR1 or N; B is CR3 or N; D is CR4 or N; L1 is -(CR7R7)m-; L2 is -(CR7R7)n-; and X, Z, R1, R2, R3, R4, R5,and R6 are define herein. Also disclosed are methods of using such compounds as modulators of TNFα, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    披露了公式(I)化合物或其盐,其中:A是CR1或N;B是CR3或N;D是CR4或N;L1是-(CR7R7)m-;L2是-(CR7R7)n-;X,Z,R1,R2,R3,R4,R5和R6都在此定义。还披露了将此类化合物用作调节TNFα的调节剂的方法,以及包含此类化合物的药物组合物。这些化合物可用于治疗炎症和自身免疫性疾病。
  • [EN] IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY<br/>[FR] DÉRIVÉS D'IMIDAZOPYRIDINE UTILISABLES EN TANT QUE MODULATEURS DE L'ACTIVITÉ TNF
    申请人:UCB PHARMA SA
    公开号:WO2014009295A1
    公开(公告)日:2014-01-16
    A series of imidazo[l,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    一系列式(I)的咪唑并[1,2-a]吡啶衍生物,作为人类TNFa活性的有效调节剂,因此在治疗和/或预防各种人类疾病方面具有益处,包括自身免疫和炎症性疾病;神经学和神经退行性疾病;疼痛和伤害感知性疾病;心血管疾病;代谢性疾病;眼科疾病;以及肿瘤学疾病。
查看更多